Promising New Three-Year Findings on LEQEMBI® Emerge from CTAD 2026 Conference

New Three-Year Findings on LEQEMBI® at CTAD 2026



As the Alzheimer's community looks for solutions, Eisai Co., Ltd. and Biogen Inc. have shared groundbreaking new findings on LEQEMBI®, a monoclonal antibody used for early Alzheimer's disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. With results gathered over three years from 560 patients across 13 clinical sites in the U.S., these findings establish LEQEMBI® as a beacon of hope for those affected by Alzheimer's disease.

Significant Progression Delays in Early Alzheimer's


Newly presented data from the LEADER study indicate that LEQEMBI® significantly delays the progression to moderate or severe Alzheimer's disease dementia by 76%, when compared to matched historical cohorts. This pivotal finding emphasizes the drug's potential to keep patients at the early stages of dementia longer, providing a better quality of life for both patients and their families.

Dr. Brent Berry from the Minneapolis Clinic of Neurology expressed that, "The LEADER study is enhancing our understanding of how the benefits observed in clinical trials transfer to everyday clinical practice." This suggests not only efficacy but also a real-world applicability of LEQEMBI®, innovative treatment strategies, and maintenance therapies.

Stability and Improvement Rates


Among the patients studied, over 81% experienced stability or improvement after an average of 18 months on treatment. This stability translates into a mitigated cognitive decline, offering patients the comfort of better managing their condition. Additionally, an impressive 87.5% continued their treatment, citing both safety and efficacy as core reasons for their persistence.

With the introduction of subcutaneous maintenance therapy and the transition to intravenous options, over 90% of patients who completed 18 months of treatment remained under LEQEMBI® therapy, showcasing strong treatment adherence. Notably, there were no reported cases of ARIA—Amyloid-Related Imaging Abnormalities, which often accompany amyloid beta-targeting treatments—during the maintenance phase, underscoring the safety of LEQEMBI® in real-world settings.

Insights Across Different Demographics


The study also revealed that outcomes were consistent across various demographics, including sex, race, and concomitant medication usage. Women and men exhibited comparable rates of stability and improvement, pointing to LEQEMBI®’s broad suitability across different populations.

Additionally, in a separate meta-analysis of roughly 5,000 patients treated in clinical practice from various countries, lower rates of ARIA were recorded compared to earlier clinical trials. This reinforces the drug's profile as a safer option in the long run.

Ongoing Commitment to Alzheimer's Research


Eisai and Biogen’s commitment to exploring and developing treatments for Alzheimer’s remains unwavering. By continually evaluating treatments’ effectiveness in diverse clinical settings, they aim to glean valuable insights that can empower patients, families, and healthcare providers toward better management of Alzheimer’s disease.

The three-year findings from the LEADER study not only offer substantial evidence backing LEQEMBI®'s effectiveness but represent a significant shift in how Alzheimer’s treatment can be understood and implemented in daily practice. This evolving narrative fills a crucial void in the quest for more effective Alzheimer’s therapies.

As the journey to combat Alzheimer’s progress continues, these findings signal not just advancements in medical science but intensely personal impacts on the lives of caregivers and patients alike. With such promising developments, the next steps in Alzheimer’s care can lead to a more hopeful future—a future where Alzheimer’s is manageable and where patients can enjoy their lives with dignity and support.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.